Xilio Therapeutics
Update in progressXLO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Xilio Therapeutics is a clinical‑stage biotechnology company developing masked immuno‑oncology therapies. Its pipeline includes XTX501, a bispecific PD‑1 / masked IL‑2 for metastatic non‑small cell lung cancer; Efarindodekin alfa, a masked IL‑12 in Phase 2 for advanced solid tumors; and Vilastobart, a tumor‑activated, Fc‑enhanced anti‑CTLA‑4 antibody. Founded in 2016 and based in Waltham, MA.
Company score
- Sentiment
- 0.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.32
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!